

SCREENING ASSAY TO IDENTIFY INHIBITORS OF THE MURD ENZYME USING AN ACTIVATOR-INDEPENDENT MURD ENZYME

The present invention relates to improved screening assays and in particular to the use of activator-independent forms of the murein biosynthesis enzyme MurD, such as from

5 *Enterococcus faecalis* (*E. faecalis*). Such screening assays are used to identify and characterize modulators of the MurD enzyme.

Interest has been shown in the murein (Mur) biosynthesis pathway in bacteria, this is a key component of bacterial cell wall synthesis. Enzymes in this pathway are potential targets for broad-spectrum and selective antibacterial agents.

10 The bacterial enzyme MurD (UDP-N-acetylmuramyl-L-alanine:D-glutamate ligase catalyses the attachment of D-glutamate to a cytoplasmic peptidoglycan precursor, UDP-N-acetylmuramyl-L-alanine. This reaction results in the formation of a peptide linkage between the amino function of D-glutamate and the carboxyl terminus of UDP-N-acetylmuramyl-L-alanine. A stoichiometric consumption of ATP supplies the energy needed for this peptide

15 bond formation resulting in generation of ADP and orthophosphate.

Walsh et al (Journal of Bacteriology, Sept 1999, 181, No.17, 5395-5401) have examined the biochemical properties of the Mur D enzyme from two gram-negative bacteria, i.e. *Escherichia coli*, and *Haemophilus influenzae*, and two gram-positive bacteria i.e. *Enterococcus faecalis* and *Staphylococcus aureus*. They established data regarding the

20 biochemical properties of these enzymes and discussed similarities and differences between them, in particular with regard to salt-activation of the gram-negative bacteria. They report that the differences observed between the gram-positive and the gram-negative bacteria indicate that the two gram-negative bacteria may apply a more stringent regulation of cell wall biosynthesis at the early stage of the peptidoglycan biosynthesis pathway than do the two

25 gram-positive bacteria. However, the skilled reader is aware that the substrate purification procedure used by Walsh et al cannot remove all salts that may function as enzyme activators. Therefore it is not possible to draw meaningful conclusions as to the salt-dependence or lack of salt dependence of the two gram-positive bacteria.

Indeed, we have now found that the MurD enzyme from the gram-positive bacterium

30 *Staphylococcus aureus* is also salt-activated. This led to our discovery that the *E. faecalis* MurD enzyme has unique properties which make it possible to devise improved screening assays using an activator-independent MurD enzyme.

Therefore in a first aspect of the present invention, we provide the use of an activator-independent MurD enzyme in a screening assay to identify inhibitors of the enzyme, which assay comprises contacting the enzyme with a test compound in the presence of an enzyme substrate and appropriate buffers and detecting any modulation of enzyme activity by the test
5 compound.

By "activator-independent" we mean that the Mur D enzyme is not activated by salt species normally associated with the substrate (here D-glutamic acid or more preferably UDP-N-acetylmuramyl-L-alanine) or other assay components. Monovalent cations such as ammonium (NH_4^+) and potassium (K^+) are particular salt species that activate Mur D. We
10 note that if different amounts of substrate are used in an assay e.g. for K_m determinations or mode of inhibition studies, the amount of the activating cation such as ammonium ions is not constant. It can therefore not be clearly identified if an activity increase is due to activation or due to an increase of substrate concentration. Contrary to the results reported by Walsh et al. we have found that the *Staphylococcus aureus* Mur D enzyme is activated by cations such as
15 NH_4^+ and K^+ (cf. Figure 2).

Our analysis shows that activator-dependent forms of the MurD enzyme have the following common amino acid residues i.e. G96, A112, A116, V126, L129, M133, G296, P298 and V422. The indicated positions are based on the *E. faecalis* Mur D sequence as set out in Figure 8 (and corresponding sequence alignments).

Therefore in a further aspect of the invention we provide the use of an activator-independent MurD enzyme which contains a MurD amino acid sequence wherein one or more of the amino acid residues at the positions given above is not as indicated for that particular amino acid. More conveniently, at least two, or at least three, or at least four, or at least five, or at least six, or at least seven, or at least 8, or all nine of the amino acid residues are not as
25 indicated.

The activator-independent MurD may conveniently contain an amino acid sequence comprising one or more of the following residues i.e. K96, C112, G116, T126, M129, L133, N296, S298 and I422. More conveniently, at least two, or at least three, or at least four, or at least five, or at least six, or at least seven, or at least 8, or all nine of the amino acid residues
30 are as indicated.

The activator-independent MurD enzyme conveniently comprises the following *E. faecalis* amino acid sequence

MKKITTYQNK KVLVLGLAKS GVSAAKLLHE LGALVTVNDA KQFDQNPDAQ
 DLLTLGIRVV TGGHPIELLD EEFELIVKNP GIPYTNPLVA EALTRKIPII
 TEVELAGQIA ECPIVGITGT NGKTTTTTMI GLLLNADRTA GEARLAGNIG
 FPASTVAQEA TAKDDLVMEL SSFQLMGIET FHPQIAVITN IFEAHLDYHG
 5 SRKEYVAAKW AIQKNMTVED TLILNWNQVE LQTLAKTTAA NVLPFSTKEA
 VEGAYLLDGK LYFNEEYIMP ADELGIPGSH NIENALAAIC VAKLKNVSNV
 QIRQTLKNFS GVPHRTQFVG EVQQRIFYND SKATNILATE MALSGFDNQK
 LLLAGGLDR GNSFDELVPA LLGLKAIVLF GETKEKLAEA AKKANIETIL
 FAENVQTAVT IAFDYSEKDD TILLSPACAS WDQYPNFEVR GEAFMQAVQQ
 10 LKESEM

or a Mur D amino acid sequence having at least 85% homology, such as 90 or 95% homology, therewith.

Alternatively the activator-independent Mur D amino acid sequence has at least 70% sequence identity with the above amino acid sequence.

15 Whilst we do not wish to be limited by theoretical considerations we believe that the
 activator-independent Mur D enzyme may have up to 16, such as up to 16, 14, 12, 10, 8, 6, 4,
 or 2, amino acids removed from the N-terminus and/or up to 12, such as up to 12, 10, 8, 6, 4,
 or 2, amino acids removed from the C-terminus of the enzyme.

20 Activator-independent Mur D sequences that do not correspond to published Mur D
 enzyme sequences are novel and represent a further aspect of the present invention.

Any convenient screening assay format may be used. By way of non-limiting example we disclose the following:

The enzyme substrates are conveniently UDP-MurNac-L-Ala, D-Glutamate and ATP.

25 The enzyme is conveniently pre-incubated with the test compound to allow inhibitors
 to bind to the enzyme. This may allow the detection of inhibitors with a slow binding mode to
 the enzyme or allow detection of specifically modifying inhibitors that may be out-competed
 by the substrates.

30 Any appropriate buffer can be used that has a pKa in the pH range where *E.faecalis*
 MurD is active (pH 7.0 – 10.0) Examples of convenient buffers include buffers that do not
 contain phosphate such as GOOD Buffer i.e. Tris or Hepes (Good, et al. (1966) Biochemistry,
 5, 467-477). Modulation of enzyme activity may be detected using any convenient detection
 system, such as those which include a colour change eg. using malachite green. These
 include absorbance spectrophotometers, absorbance plate reader or any other instrument that

can determine the absorption of a solution between for example a wavelength range of 400 to 800 nm

Modulation of enzyme activity can be inhibition or activation of enzyme activity, conveniently enzyme inhibition.

- 5 Appropriate control reactions are conveniently performed to determine if a chemical compound interferes with the detection system and/or has an absorbance at the detection wavelength.

10 The test compound is any convenient compound that may be useful in pharmaceutical research. It may be a polypeptide of equal to or greater than, 2 amino acids such as up to 6 amino acids, up to 10 or 12 amino acids, up to 20 amino acids or greater than 20 amino acids such as up to 50 amino acids. For drug screening purposes, preferred compounds are chemical compounds of low molecular weight and potential therapeutic agents. They are, for example of molecular mass less than about 1000 Daltons, such as less than 800, 600 or 400 Daltons. If desired, the test compound may be a member of a chemical library. This may
15 comprise any convenient number of individual members, for example, tens to hundreds to thousands to millions etc., of suitable compounds, for example, peptides, peptoids and other oligomeric compounds (cyclic or linear), and template-based smaller molecules, for example, benzodiazepines, hydantoins, biaryls, carbocyclic and polycyclic compounds (eg. naphthalenes, phenothiazines, acridines, steroids etc.), carbohydrate and amino acids
20 derivatives, dihydropyridines, benzhydryls and heterocycles (eg. triazines, indoles, thiazolidines etc.). The numbers quoted and the types of compounds listed are illustrative, but not limiting. Preferred chemical libraries comprise chemical compounds of low molecular weight and potential therapeutic agents.

- 25 In a further aspect of the invention we provide a MurD enzyme modulator resulting from use of the assay method of the invention.

30 The activator-independent MurD enzyme may be produced using known recombinant techniques for cloning and expression (cf. Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. Molecular cloning: a laboratory manual, 2nd ed. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.). Convenient expression systems for the MurD enzyme include T7 promoter-driven transcription of the *murD* gene in a suitable host, more conveniently *E. coli*. Examples of convenient expression vectors include those with a T7 promoter and suitable cloning sites such as pET28b and pET30a (Novagen Inc. Madison WI USA). The *E. coli* host strains used for expression in such a system include those that contain the T7 RNA polymerase gene that

can be induced to initiate transcription of the *murD* gene, more specifically BL21(DE3) and HMS174(DE3).

The invention will now be illustrated by reference to the following Specific Description and Figures wherein:

5

Figure 1 shows the lack of salt activation for *E. faecalis* MurD and shows that all salts but SO₄-ions (=inhibitor) have no effect on *E. faecalis* MurD

Figure 2 shows the salt activation of *S. aureus* MurD

10

Figure 3 shows that the *E. coli* enzyme activity is dependent on the presence of ammonium formate while the *E. faecalis* enzyme activity is independent on the presence of this salt.

Figure 4 shows the stability of *E. faecalis* Mur D in DMSO at concentrations of up to 5%.

15

Figure 5 shows a graph (Eyring Plot) with the activation enthalpies for several MurD orthologues, including *E. faecalis*. The higher this value the more temperature dependent the reaction rate

20 Figure 6 (a) and (b) show the pH dependence of several MurD orthologues, including *E. faecalis*

Figure 7 shows the background ATPase activity of several MurD orthologues, including *E. faecalis*.

25

Specific Description:

We have established that the *E. faecalis* MurD enzyme has the following additional advantages for screening purposes compared to MurD enzymes from other species.

(a) it is not affected up to a dimethylsulfoxide (DMSO) concentration of 5%. Since DMSO is
5 commonly used in screening and IC₅₀ measurements, this contributes to the stability of the assay results.

(b) its dependence of the reaction rate on temperature is low between 4°C to 40°C.

Temperature variations during assays have only a minor effect on the enzyme activity.

(c) it has the broadest pH optimum (pH 7.5 – 9.5). Changes in pH due to compound addition
10 is less likely to affect activity and therefore assay results

(d) it has a low background ATPase activity. An idle ATPase activity can create a background signal in a screen (phosphate is being produced without catalysis occurring) so a low amount of this activity is desirable to produce a sensitive assay.

15 We devised a screening assay for this ortholog using Malachite Green for detection of the phosphate product. The assay includes controls to check for compound interference with the signal and interference with the detection method.

1. Compounds are preincubated with *E. faecalis* MurD for 5-30 min.

2. The 3 substrates ATP, UDP-MurNac-L-Ala and D-Glutamate are added to initiate the
20 reaction.

3. After 30-60 min the reaction is stopped with a Malachite Green solution. The signal is recorded spectrophotometrically 4-10 min after the Malachite Green solution had been added.

To control for compound interference with the assay signal, compounds are submitted to the same procedure but in the absence of *E. faecalis* MurD in step 1. Compounds interfering
25 with the signal show an increased signal relative to a control where no *E. faecalis* MurD was present

To control for compound interference with the Malchite Green detection method, a constant amount of phosphate (10-15 uM) is replaced for *E. faecalis* MurD in step 1. Interference is detected by a increase or decrease of the signal relative to a control where no compound was
30 present.

Specific assay conditions are 0.3nM *E. faecalis* MurD in 50mM Tris, 2.5mM DTT, 10mM MgCl₂, 0.01% Triton X-100, 50 uM ATP, 50uM UMA, 100uM D-Glu, pH 8.0. Typically

MurD is preincubated with inhibitor for 15 min in the absence of substrates. Subsequently the reaction is initiated by adding substrates and stopped by addition of Malachite Green after 60min. Signal is read 5 min after stopping the reaction. Although MurD activity is detected in this assay by formation of phosphate it is not limited to this detection method and can also be

5 followed alternatively, for example, by measuring formation of other reaction products (UDP-N -acetylmuramyl-L-alanine-D-Glutamate, ADP) as well as the disappearance of the substrates (D-Glutamate, UDP-N-acetylmuramyl-L-alanine, ATP).